Atherosclerosis
Volume 212, Issue 1 , Pages 40-41 , September 2010

Newly appreciated therapeutic effect of GLP-1 receptor agonists: Reduction in postprandial lipemia

  • Robert H.J. Bandsma
    • ,
  • Gary F. Lewis

      Affiliations

    • Corresponding Author InformationCorresponding author at: Toronto General Hospital, 200 Elizabeth Street, EN12-218 Toronto, Ontario, Canada M5G 2C4. Tel.: +1 416 340 4270; fax: +1 416 340 3314.

Received 14 June 2010 ,Accepted 15 June 2010.

References 

  1. Lewis GF. Postprandial lipoprotein metabolism in diabetes mellitus and obesity. J Atheroscler Thromb. 1995;2(Suppl. 1):S34–S35
  2. Adeli K, Lewis GF. Intestinal lipoprotein overproduction in insulin-resistant states. Curr Opin Lipidol. 2008;19:221–228
  3. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165
  4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705
  5. Qin X, Shen H, Liu M, et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol. 2005;288:G943–G949
  6. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010;53:552–561
  7. Schwartz SL, Ratner RE, Kim DD, et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther. 2008;30:858–867
  8. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943–2952
  9. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49:2049–2057
  10. Meier JJ, Gethmann A, Gotze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006;49:452–458
  11. Schwartz EA, Koska J, Mullin MP, et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 2010;212:217–222
  12. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:2719–2725
  13. Tolessa T, Gutniak M, Holst JJ, et al. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci. 1998;43:2284–2290
  14. Parlevliet ET, Schroder-van der Elst JP, Corssmit EP, et al. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J Pharmacol Exp Ther. 2009;328:240–248
  15. Pavlic M, Xiao C, Szeto L, et al. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes. 2010;59:580–587

PII: S0021-9150(10)00451-X

doi: 10.1016/j.atherosclerosis.2010.06.033

Atherosclerosis
Volume 212, Issue 1 , Pages 40-41 , September 2010

Article Tools